General
Preferred name
vinblastine
Synonyms
VINBLASTINE SULFATE ()
NSC49842 ()
Vinblastine (sulfate) ()
Vincaleukoblastine sulfate salt ()
29060LE ()
Vincaleukoblastine sulfate ()
Vinblastine sulphate ()
NSC-49842 ()
29060-LE ()
Vinblastini sulfas ()
Vinblast,lederle ()
VLB monosulfate ()
Velbe ()
Velban ()
Alkaban-aq ()
[3H]-Vinblastine ()
Vinblastina ()
NSC-47842 ()
P&D ID
PD013748
CAS
865-21-4
18556-44-0
132142-72-4
143-67-9
Tags
available
drug
Approved by
FDA
First approval
1965
Drug indication
Cutaneous melanoma
Hodgkins lymphoma
Solid tumour/cancer
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
A pan tubulin inhibitor that is a chemical analogue of (from Catharanthus roseus, also known as Vinca rosea). There is some ambiguity surrounding the exact stereochemistry of vinblastine. The chirality shown here corresponds to the PubChem CID provided on the Summary tab. However, bioactivity data for the compound is also listed against CID 241903, and some of the external resource links refer to this chiral specification or others. Marketed formulations contain vinblastine sulfate (PubChem CID 5388983).
(GtoPdb)
PRICE
65
DESCRIPTION
Vinblastine inhibits microtubule formation and suppresses nAChR activity with IC50 of 8.9 ??M, used to treat certain kinds of cancer.
DESCRIPTION
Vinblastine sulfate is a cytotoxic alkaloid used against various cancer types. Vinblastine sulfate inhibits the formation of microtubule and suppresses nAChR with an IC50 of 8.9 ¦ÌM.
DESCRIPTION
Vinblastine inhibits microtubule formation and suppresses nAChR activity with IC50 of 8.9 μM, used to treat certain kinds of cancer.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Vinblastine sulfate is a cytotoxic alkaloid used against various cancer types. Vinblastine sulfate inhibits the formation of microtubule and suppresses nAChR.
(Enamine Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
622
Organisms
4
Compound Sets
27
Cayman Chemical Bioactives
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Reference compounds for characterizing cellular injury in high-content cellular morphology assays
ReFrame library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
60
Molecular Weight
810.42
Hydrogen Bond Acceptors
12
Hydrogen Bond Donors
3
Rotatable Bonds
7
Ring Count
9
Aromatic Ring Count
3
cLogP
3.99
TPSA
154.1
Fraction CSP3
0.59
Chiral centers
10.0
Largest ring
9.0
QED
0.18
Structural alerts
1
Tubulin modulation
Nuisance compounds
Related compounds
Custom attributes
(extracted from source data)
MOA
tubulin polymerization inhibitor
AChR inhibitor
Tubulin modulator
Microtubule assembly inhibitor
microtubule inhibitor, tubulin polymerization inhibitor
Target
Tubulin
Microtubule Associated
nAChR
JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1
Autophagy
Microtubule/Tubulin
Pathway
Neuroscience
Cytoskeletal Signaling
Cell Cycle/DNA Damage
cytoskeleton
Membrane Transporter/Ion Channel
Neuronal Signaling
Member status
virtual
Disease Area
hematologic malignancy, infectious disease, oncology
Indication
Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma
Cellular injury category
Cytoskeletal
Therapeutic Class
Anticancer Agents
Source data
